Quarterly report [Sections 13 or 15(d)]

Note 1 - Organization, Plan of Business Operations (Details Textual)

v3.25.2
Note 1 - Organization, Plan of Business Operations (Details Textual) - USD ($)
Apr. 24, 2025
Feb. 28, 2023
Jun. 30, 2025
Dec. 31, 2024
Retained Earnings (Accumulated Deficit)     $ (104,097,000) $ (102,580,000)
AnnJi [Member]        
License Agreement, Purchase Consideration   $ 3,000,000    
Maximum Reimbursement Amount In Connection With Product Clinical Trial   10,800,000    
Maximum Reimbursement Amount In Connection With Certain Development Milestones   14,500,000    
Maximum Reimbursement Amount In Connection With Certain Drug Development Milestone   27,500,000    
Maximum Reimbursement Amount Upon Achievement of Sales Milestone   165,000,000    
Payments for Repurchase of Common Stock $ 1      
Payments Upon Termination of Agreement 200,000      
Termination Payments Receivable $ 1,600,000      
License Agreement, Tax Withholding, Percent 20.00%      
Termination Payments Receivable Within Thirty Days $ 800,000      
Termination Payments Receivable Within Ninety Days 800,000      
Eligible Termination Payments, Development and Regulatory Milestones 5,000,000      
Eligible Termination Payments, Commercial Sales Milestones $ 17,000,000      
Eligible Termination Payments, Royalty Percentage on Net Sales 1.75%      
Eligible Termination Payments, Percentage of Subsequent Licensees 15.00%      
AnnJi [Member] | Minimum [Member]        
Sales Milestone Required for Maximum Reimbursement   75,000,000    
Eligible Termination Payments, Subsequent Licensees $ 4,000,000      
AnnJi [Member] | Maximum [Member]        
Sales Milestone Required for Maximum Reimbursement   $ 750,000,000    
Eligible Termination Payments, Subsequent Licensees $ 7,500,000